Biotechnology Platform
Developing New Technologies in Health Diagnostics.
Leaders in New Analyte Detection Methods.
Developing New Technologies in Health Diagnostics.
Leaders in New Analyte Detection Methods.
Founded in 2016 with investment to conduct research into the development of a new generation of low cost and self-diagnostic tests for allergens and food intolerances.
Summer of 2021, a PCT file with the International Patent Office for our a Analyte Detection Method using recombinant proteins, produced in E.Coli.
The system has demonstrated its flexibility in the platform when testing various antigens. Being tested with both Rapamycin and SARS-CoV-2 Spike protein.
Designed to create rapid, self-contained diagnostic devices.
Assay designed to take less than 30 minutes. Trials demonstrating results in less than 5 minutes.
Requires no additional equipment. Designed to be an independent system, without the requirement for additional equipment.
Utilizes recombinant proteins produced in E.Coli. A lower sunk cost requirement for a production facility along with a lower per-unit-cost than current antibody tests.
We are an impact driven organization interested in increasing accessibility to high quality healthcare in developing nations. The need for highly specialized technology with scalability in mind, remains evident as the ever increasing demand of diagnostics around the world continues.
The pandemic has demonstrated humanities reliance on scalable and affordable technologies when it comes to diagnostics. We are paving the way for a new type of diagnostics for the developing world. As of now, there is not enough trained medical professionals in the developing world to manage all of the scans being taken. In addition to this, it is too costly as of yet.